Loading clinical trials...
Loading clinical trials...
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Conditions
Interventions
Otilimab (GSK3196165)
csDMARD(s)
Locations
375
United States
GSK Investigational Site
Anniston, Alabama, United States
GSK Investigational Site
Flagstaff, Arizona, United States
GSK Investigational Site
Gilbert, Arizona, United States
GSK Investigational Site
Glendale, Arizona, United States
GSK Investigational Site
Mesa, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
Start Date
May 12, 2020
Primary Completion Date
February 24, 2023
Completion Date
February 24, 2023
Last Updated
February 7, 2024
NCT07017686
NCT05038553
NCT05790356
NCT03429426
NCT06028438
NCT06800157
Lead Sponsor
GlaxoSmithKline
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions